Department of infectious diseases, Yiwu Central Hospital, No. 519 Nanmen Street, Yiwu, 322000, China.
BMC Gastroenterol. 2020 Apr 9;20(1):98. doi: 10.1186/s12876-020-01222-1.
Statin may confer anticancer effect. However, the association between statin and risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) or hepatitis C (HCV) virus infection remains inconsistent according to results of previous studies. A meta-analysis was performed to summarize current evidence.
Related follow-up studies were obtained by systematic search of PubMed, Cochrane's Library, and Embase databases. A random-effect model was used to for the meta-analysis. Stratified analyses were performed to evaluate the influences of study characteristics on the outcome.
Thirteen studies with 519,707 patients were included. Statin use was associated with reduced risk of HCC in these patients (risk ratio [RR]: 0.54, 95% CI: 0.44 to 0.66, p < 0.001; I = 86%). Stratified analyses showed that the association between statin use and reduced HCC risk was consistent in patients with HBV or HCV infection, in elder (≥ 50 years) or younger (< 50 years) patients, in males or females, in diabetic or non-diabetic, and in those with or without cirrhosis (all p < 0.05). Moreover, lipophilic statins was associated with a reduced HCC risk (RR: 0.52, p < 0.001), but not for hydrophilic statins (RR: 0.89, p = 0.21). The association was more remarkable in patients with highest statin accumulative dose compared to those with lowest accumulative dose (p = 0.002).
Satin use was independently associated with a reduced risk of HCC in patients with HBV or HCV infection.
他汀类药物可能具有抗癌作用。然而，根据先前研究的结果，他汀类药物与乙型肝炎病毒（HBV）或丙型肝炎病毒（HCV）感染患者肝癌（HCC）风险之间的关联并不一致。进行了一项荟萃分析以总结当前的证据。
通过系统搜索 PubMed、Cochrane 图书馆和 Embase 数据库获得相关随访研究。使用随机效应模型进行荟萃分析。进行分层分析以评估研究特征对结果的影响。
纳入了 13 项研究，共 519707 名患者。他汀类药物的使用与这些患者 HCC 风险降低相关（风险比 [RR]：0.54，95%CI：0.44 至 0.66，p<0.001；I=86%）。分层分析表明，他汀类药物的使用与 HCC 风险降低之间的关联在 HBV 或 HCV 感染、年龄（≥50 岁或<50 岁）、男性或女性、糖尿病或非糖尿病以及伴或不伴肝硬化的患者中是一致的（均 p<0.05）。此外，亲脂性他汀类药物与 HCC 风险降低相关（RR：0.52，p<0.001），而亲水性他汀类药物则不然（RR：0.89，p=0.21）。与累积剂量最低的患者相比，累积剂量最高的患者的相关性更为显著（p=0.002）。
他汀类药物的使用与 HBV 或 HCV 感染患者 HCC 风险降低独立相关。
